Perrigo Company plc Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation
Perrigo Company plc (PRGO) reported Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation of $800.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation · last filed 2025-02-28
- Perrigo Company plc unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2024 was $800.00K.
- Perrigo Company plc unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2022 was $900.00K, a 30.77% decline from fiscal 2021.
- Perrigo Company plc unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2021 was $1.30M, a 18.75% decline from fiscal 2020.
- Perrigo Company plc unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2020 was $1.60M, a 128.57% increase from fiscal 2019.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation 12 month |
|---|---|
| 2024-12-31 | $800.00K 10-K · filed 2025-02-28 |
| 2022-12-31 | $900.00K 10-K · filed 2024-02-27 |
| 2021-12-31 | $1.30M 10-K · filed 2023-02-28 |
| 2020-12-31 | $1.60M 10-K · filed 2022-03-01 |
| 2019-12-31 | $700.00K 10-K · filed 2021-03-01 |
| 2018-12-31 | $3.00M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |